Evidence map›Paper›PMID 35072838›Full record

ArticleMolecular diversity2022

Detection of polypharmacy side effects by integrating multiple data sources and convolutional neural networks.

Amir Lakizadeh, Mahdi Babaei

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amir LakizadehComputer Engineering Department, University of Qom, Qom, Iran. lakizadeh@qom.ac.ir.ORCID http://orcid.org/0000-0001-9870-3676
Mahdi BabaeiComputer Engineering Department, University of Qom, Qom, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The consumption of drug combinations, named polypharmacy, is commonly used for treating patients with several diseases or those with complex conditions. However, the main drawback of polypharmacy is the increased probability of harmful side effects. The polypharmacy side effects are caused by an interaction between two medications. It means that the drug-drug interaction causes changes in their activities due to interfering in each other's performance. Therefore, discovering these side effects is one of the most challenging and important aspects of drug production and consumption as it is associated with human health. In this paper, a method has been introduced for predicting the polypharmacy side effects, called PSECNN. It is a multi-label multi-class deep learning method that combines various basic features of drugs to predict the polypharmacy side effects. Firstly, PSECNN collects five basic features of drugs, such as individual drug's side effects, drug-protein interactions, chemical substructures, targets, and enzymes in order to create a novel combination of drug features. A feature extraction module creates five feature vectors with the same dimension for each drug based on the Jaccard similarity index. Based on the feature vectors, a unique representative is then created for each drug. These representative vectors are given in pairs as input to the deep neural network to predict the occurrence probability of side effects. According to the experimental evaluations, PSECNN could outperform the state-of-the-art polypharmacy side effects prediction methods up to 74%. It has been found that PSECNN has better performance with polypharmacy side effects with a cause of molecular basis due to the novel combination of basic drug features.

Indexed as

Drug-Related Side Effects and Adverse ReactionsPolypharmacyHumansInformation Storage and RetrievalNeural Networks, ComputerProteinsProteinsDeep learningDrug–Drug interactionDrug repurposingPolypharmacy side effects

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.